150 related articles for article (PubMed ID: 36374396)
1. Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia.
Nakamura Y; Itoh Y; Wakimoto N
Int J Hematol; 2023 Apr; 117(4):613-617. PubMed ID: 36374396
[TBL] [Abstract][Full Text] [Related]
2. Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag.
Autore F; Sora' F; Chiusolo P; Minnella G; Colangelo M; Rossi E; Sica S
Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946271
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia.
Aleem A; Alotaibi G; Iqbal Z; AlFaifi A
Int J Hematol; 2023 Aug; 118(2):288-291. PubMed ID: 36892804
[TBL] [Abstract][Full Text] [Related]
4. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
5. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Aribi A; Kantarjian H; Koller C; Thomas D; Faderl S; Garcia-Manero G; Cortes J
Cancer; 2008 Sep; 113(6):1338-43. PubMed ID: 18629842
[TBL] [Abstract][Full Text] [Related]
6. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
7. Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience.
Cojbasić I; Macukanović-Golubović L
Vojnosanit Pregl; 2010 Oct; 67(10):802-6. PubMed ID: 21061842
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Survival of Patients with Chronic Myeloid Leukemia Treated with Imatinib in the Last 15 Years in Lebanon.
Massoud M; Sakr R; Kerbage F; Makdissi J; Hawi J; Rached L; Nasr F; Chahine G
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S111-S115. PubMed ID: 28760296
[TBL] [Abstract][Full Text] [Related]
12. A Case Report of Successful Kidney Transplantation in a Patient With Chronic Myelogenous Leukemia (CML) Who Has Been in Remission for 15 Years on Imatinib.
Tokumoto T; Setoguchi K; Osaka A; Ikezoe E; Tsujioka H; Hasegawa K; Inoue M; Nirazuka A; Iwahata T; Inoue Y; Saito K
Transplant Proc; 2023 May; 55(4):1074-1077. PubMed ID: 37147192
[TBL] [Abstract][Full Text] [Related]
13. Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy.
Nakamura F; Arai H; Nannya Y; Ichikawa M; Furuichi S; Nagasawa F; Takahashi W; Handa T; Nakamura Y; Tanaka H; Nakamura Y; Sasaki K; Miyano S; Ogawa S; Mitani K
Int J Hematol; 2021 Jun; 113(6):936-940. PubMed ID: 33400143
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.
Usuki K; Tojo A; Maeda Y; Kobayashi Y; Matsuda A; Ohyashiki K; Nakaseko C; Kawaguchi T; Tanaka H; Miyamura K; Miyazaki Y; Okamoto S; Oritani K; Okada M; Usui N; Nagai T; Amagasaki T; Wanajo A; Naoe T
Int J Hematol; 2012 Apr; 95(4):409-19. PubMed ID: 22359103
[TBL] [Abstract][Full Text] [Related]
15. Effects of tyrosine kinase inhibitors for controlling Ph+ clone and additional clonal abnormalities in a chronic myeloid leukemia.
Ganguly BB; Mandal S; Banerjee D; Kadam NN
J Cancer Res Ther; 2022; 18(3):760-764. PubMed ID: 35900551
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia.
Tadesse F; Asres G; Abubeker A; Gebremedhin A; Radich J
JCO Glob Oncol; 2021 Jul; 7():1187-1193. PubMed ID: 34292760
[TBL] [Abstract][Full Text] [Related]
18. Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate.
Maral S; Bakanay SM; Yikilmaz AS; Dilek I
J Cancer Res Ther; 2018; 14(6):1431-1433. PubMed ID: 30488870
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
20. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]